Meeting
2024 ASCO Genitourinary Cancers Symposium
Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.
Presenter
Matthew Nicholas Young, MD, BSc
Barts Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Rapid Oral Abstract Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 534)
DOI
10.1200/JCO.2024.42.4_suppl.534
Abstract #
534
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2018 ASCO Annual Meeting
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
Speaker: Thomas Powles, MD
Speaker: Suzanne Louise Topalian, MD
Videos & Slides
2023 ASCO Annual Meeting
APP Insights: Onboarding, Scope of Practice, and Maximizing Practice
Speaker: Todd Alan Pickard, FASCO
Videos & Slides
2022 ASCO Annual Meeting
Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.
Speaker: Sumanta K. Pal, MD, FASCO